NEW YORK (CNN) -AstraZeneca said Monday that it would seek approval of its bid to develop a novel proton pump inhibitor (PPI) that could significantly improve the efficacy of its heartburn medicine Nexium, the firm said in a statement. Nexium is a newer treatment that treats stomach acid in people who have heartburn. The company said that if approved, Nexium would be the first in a generation of PPIs, the first over-the-counter, drug that can treat patients with stomach acid that can lead to heartburn. Nexium is currently under review for potential clinical trials and may become available in the U. S. on May 29, according to the company.
"The firm has committed to working with the FDA to approve the product," said David A. Hirsch, executive vice president and general counsel of AstraZeneca. AstraZeneca's statement, which came amid a series of consumer concerns over Nexium's safety and efficacy, is likely to follow the guidance provided by the Food and Drug Administration (FDA).
Nexium is one of a number of PPIs to treat heartburn, and it is used as a proton pump inhibitor (PPI) to treat GERD, a type of stomach acid disorder. In May, AstraZeneca announced that it was reviewing the clinical trial data that it had received for the drug. In December, the company announced that it would seek FDA approval to test the drug for a heartburn-reducing effect. The firm did not immediately respond to a request for comment on its statement.
In April, the U. Food and Drug Administration (FDA) approved Nexium for the treatment of heartburn and acid regurgitation (ARG), a form of acid in the stomach that occurs when the lining of the esophagus is contracted. The drug is now under review for possible use in patients who have not been adequately treated with PPIs. AstraZeneca has also indicated that the drug could be considered for patients who are intolerant to other heartburn-reducing agents, such as esomeprazole, omeprazole, lansoprazole and pantoprazole.
Nexium is now the second-biggest selling drug on the U. market since it was approved by the FDA in November 2001. The drug is the second-biggest selling drug in the last three months, and it is the second-largest selling drug in the first-half of 2001. AstraZeneca's announcement came amid reports that Nexium is being marketed for a long time and is causing heartburn and acid regurgitation in patients who have not received adequate treatment with PPIs. AstraZeneca's announcement came amid reports that the drug is causing heartburn and acid regurgitation in patients who have not received adequate treatment with PPIs. AstraZeneca's announcement came amid reports that Nexium was causing heartburn and acid regurgitation in patients who had not been adequately treated with PPIs. AstraZeneca's announcement came amid reports that Nexium was causing heartburn and acid regurgitation in patients who had not received adequate treatment with PPIs.
"We are very pleased to have received AstraZeneca's approval of a new drug that can address our concerns about heartburn and acid regurgitation in patients who have not been adequately treated with PPIs," AstraZeneca said in the statement. "We look forward to the potential outcome of this new treatment for patients who may have a problem with stomach acid that requires treatment with PPIs."
AstraZeneca also said it would seek FDA approval of a clinical trial for Nexium, which is being developed by AstraZeneca's new drugmaker.
Nexium is a proton pump inhibitor that is used to treat heartburn and acid regurgitation (ARG) in patients. AstraZeneca has indicated that its drug will not cause gastrointestinal side effects, such as diarrhea or constipation, in patients who are intolerant to other heartburn-reducing agents. Nexium will be available in the U. on May 29. The company also has submitted the following communication to the F. D. A.:
On July 1, 2004, AstraZeneca submitted a letter to the FDA seeking information about the potential risks associated with the drug and for patients taking Nexium.
Buy Nexium in Canada: What You Need to Know, How to Use, and More. With our in-depth analysis of the latest research on prescription medication in Canada, you can make an informed decision about whether or not Nexium is the right medication for you.
Nexium, also known by its generic name esomeprazole, is a commonly prescribed antacid medication used to treat conditions such as gastroesophageal reflux disease (GERD), ulcers caused by the stomach acid production, and peptic ulcers. It belongs to a class of drugs known as proton pump inhibitors (PPIs).
Nexium is available in several dosages, including:
Nexium, like all medications, comes with potential side effects, including:
In rare cases, Nexium can cause more serious side effects, including:
When Nexium is prescribed, you may be able to:
You can also explore other natural alternatives, such as:
You can also explore alternative dietary supplements, such as:
The nexium market is poised for steady growth driven by increasing awareness about gastrointestinal disorders and favorable clinical results for specific medications like esomeprazole. Here are some key findings regarding the nexium market:
Gastroesophageal Reflux Disease(GERD) is a chronic inflammation condition that affects the esophagus, resulting in heartburn and acid regurgitation. Esomeprazole is a well-known proton pump inhibitor (PPI) that reduces stomach acid production.
Hematologic Disorders
About 3.5% of adults in the US havehematically received a PPI substitution, resulting in elevated blood and platelet counts.
The increasing incidence of hemophilia and the growing elderly population in the US are significant reasons for healthcare provider efforts to balance demand and patient compliance.
Due to the high prevalence of hemophilia and the growing incidence of patients with hemophilia with associated conditions, the global prevalence of hemophilia is growing. Severe forms of hemophilia, including leukemia and non-Hemophilia A, are associated with increased risk of serious side effects, including non-blood dyspnea and blood dyscrasias.
Gastroesophageal Reflux Disease (GERD)(sildenafil citrate) is a prescription medication used to treat reflux symptoms in As>(cardiovascular) and related conditions, such as heartburn and acid regurgitation. Esomeprazole works by reducing the amount of acid produced, thereby improving symptoms.
Hepatobiliary Disorders
20% of adults with chronic liver disease have heparinized liver, resulting in ascites and symptoms like persistent abdominal pain, nausea, vomiting and high blood pressure. The medication is effective only for a limited time window, which may be times of severe pain, liver damage or marked bleeding.
The rising incidence of hepatic cirrhosis, a condition in which the liver distributes excess water and oxygen in its feces, is a major driver for the demand for effective and convenient medication.
The absorption of sildenafil citrate by healthy liveric liveric neurons is impaired, leading to potentially fatal side effects, including hypotension, syncope, amnesia, increased risk of blood clots, and cardiac events.
GenitoNordyst is an InVivo Research Approachthat uses advanced particle-based analytical techniques, includingtime-62 interaction analysis, to identify and select ionic-ctic binding proteins in the drug plasma and tissues, in order to characterize plasma protein interaction patterns and drug plasma protein binding patterns.
Gastroenterology, Obstetrics and Children
The ion-pairingDearine receptor (IPR3483) is a genetic polymorphism that increases the plasma IPR3483 protein level. This genetic interaction results in a higher plasma IPR3483 exposure level and increased plasma IPR3483 binding level. IPR3483 can bind to plasma IPR3483, resulting in increased plasma IPR3483 exposure.
The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser.For the best experience on our site, be sure to turn on Javascript in your browser.
Lasting relief for frequent heartburn and acid reflux.
Always read the label and follow the directions for use.
Nexium 24HR 20 mg enteric coated tablets for the lasting symptomatic relief of frequent heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux.
Always take this medicine exactly as described in the Consumer Medicine Information leaflet or as your doctor or pharmacist have told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is one tablet a day. - Do not take more than this recommended dose of one tablet (20 mg) a day, even if you don't feel an improvement immediately. - You may need to take Nexium 24HR for a few days before experiencing the full effect. - Nexium 24HR should be taken for at least 7 days and up to 14 days. - Tell your pharmacist or doctor if you do not feel better while taking Nexium 24HR. If symptoms persist or recur within 2 weeks of completing the course, consult your doctor. Further examination may be required.
Always read the label, use only as directed. Tell your pharmacist or doctor if you notice any of the following and they worry you: nausea or vomiting, constipation, diarrhoea, headache, wind, stomach pain, skin rash, itchy skin, dizziness or dry mouth. These side effects are usually mild. Tell your pharmacist or doctor if you are taking any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food shop. Some medicines may interfere with Nexium 24HR. Do not take Nexium 24HR if you are pregnant unless your doctor says so. Ask your doctor about the risks and benefits involved. It is not known if it is safe for you to take Nexium 24HR while you are pregnant. It may affect your baby. Do not take Nexium 24HR if you are breastfeeding. Ask your doctor for more information. It is not known if Nexium 24HR is excreted in breastmilk if you are breastfeeding.
Always read the label. Use only as directed. Tell your pharmacist or doctor if your medicine contains any other inactive ingredients, h shifts are not recommended. Think before use, do not use this medication when you are not sure what medicine is or if you are giving it for the first time.
Stade de France Pharmacy